Overview

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Status:
Active, not recruiting

Trial end date:
2024-10-31

Target enrollment:

Participant gender:

Summary

This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma. The immunotherapy involved in this study is: - Pembrolizumab (MK-3475 or KEYTRUDA).

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab